FDA Approves First Oral Treatment for Dermatomyositis
Source Summary
The FDA has approved brepocitinib (Lisraya), the first oral treatment option for dermatomyositis, a rare autoimmune disorder. The drug is indicated for adults with the condition, which causes chronic inflammation and progressive muscle weakness.
Why it matters
This approval provides patients with dermatomyositis their first oral medication option, expanding treatment accessibility for this rare autoimmune condition.
